263 related articles for article (PubMed ID: 31368081)
21. Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer.
Yoo SK; Song YS; Lee EK; Hwang J; Kim HH; Jung G; Kim YA; Kim SJ; Cho SW; Won JK; Chung EJ; Shin JY; Lee KE; Kim JI; Park YJ; Seo JS
Nat Commun; 2019 Jun; 10(1):2764. PubMed ID: 31235699
[TBL] [Abstract][Full Text] [Related]
22. Genomic Alterations in Fatal Forms of Non-Anaplastic Thyroid Cancer: Identification of
Ibrahimpasic T; Xu B; Landa I; Dogan S; Middha S; Seshan V; Deraje S; Carlson DL; Migliacci J; Knauf JA; Untch B; Berger MF; Morris L; Tuttle RM; Chan T; Fagin JA; Ghossein R; Ganly I
Clin Cancer Res; 2017 Oct; 23(19):5970-5980. PubMed ID: 28634282
[No Abstract] [Full Text] [Related]
23. Noninvasive anaplastic thyroid carcinoma: report of a case and literature review.
Dibelius G; Mehra S; Clain JB; Urken ML; Wenig BM
Thyroid; 2014 Aug; 24(8):1319-24. PubMed ID: 24865498
[TBL] [Abstract][Full Text] [Related]
24. Diallyl trisulphide, a H
Zhang L; Xu S; Cheng X; Zheng J; Wang Y; Wu J; Wang X; Wu L; Yu H; Bao J
Phytother Res; 2021 Jun; 35(6):3428-3443. PubMed ID: 33751676
[TBL] [Abstract][Full Text] [Related]
25. The efficacy of HRAS and CDK4/6 inhibitors in anaplastic thyroid cancer cell lines.
Lopes-Ventura S; Pojo M; Matias AT; Moura MM; Marques IJ; Leite V; Cavaco BM
J Endocrinol Invest; 2019 May; 42(5):527-540. PubMed ID: 30191474
[TBL] [Abstract][Full Text] [Related]
26. Molecular Biomarkers of Anaplastic Thyroid Carcinoma.
Bozorg-Ghalati F; Hedayati M
Curr Mol Med; 2017; 17(3):181-188. PubMed ID: 28828971
[TBL] [Abstract][Full Text] [Related]
27. Metastasis to Stomach in a Patient with Anaplastic Thyroid Carcinoma: A Clinical Challenge.
Fuladi R; Nagarkar R; Roy S
Am J Case Rep; 2019 Feb; 20():134-138. PubMed ID: 30705249
[TBL] [Abstract][Full Text] [Related]
28. Anaplastic Thyroid Carcinoma: Cytomorphologic Features on Fine-Needle Aspiration and Associated Diagnostic Challenges.
Podany P; Abi-Raad R; Barbieri A; Garritano J; Prasad ML; Cai G; Adeniran AJ; Gilani SM
Am J Clin Pathol; 2022 Apr; 157(4):608-619. PubMed ID: 34661606
[TBL] [Abstract][Full Text] [Related]
29. CSPG4 Is a Potential Therapeutic Target in Anaplastic Thyroid Cancer.
Egan CE; Stefanova D; Ahmed A; Raja VJ; Thiesmeyer JW; Chen KJ; Greenberg JA; Zhang T; He B; Finnerty BM; Zarnegar R; Jin MM; Scognamiglio T; Dephoure N; Fahey T; Min IM
Thyroid; 2021 Oct; 31(10):1481-1493. PubMed ID: 34078123
[No Abstract] [Full Text] [Related]
30. Anaplastic thyroid cancer: prevalence, diagnosis and treatment.
Chiacchio S; Lorenzoni A; Boni G; Rubello D; Elisei R; Mariani G
Minerva Endocrinol; 2008 Dec; 33(4):341-57. PubMed ID: 18923370
[TBL] [Abstract][Full Text] [Related]
31. Identification of novel therapeutic targets in anaplastic thyroid carcinoma using functional genomic mRNA-profiling: Paving the way for new avenues?
Jonker PK; van Dam GM; Oosting SF; Kruijff S; Fehrmann RS
Surgery; 2017 Jan; 161(1):202-211. PubMed ID: 27865593
[TBL] [Abstract][Full Text] [Related]
32. LncRNA PTCSC3 affects drug resistance of anaplastic thyroid cancer through STAT3/INO80 pathway.
Wang XM; Liu Y; Fan YX; Liu Z; Yuan QL; Jia M; Geng ZS; Gu L; Lu XB
Cancer Biol Ther; 2018 Jul; 19(7):590-597. PubMed ID: 29561707
[TBL] [Abstract][Full Text] [Related]
33. Effects of nutraceuticals on anaplastic thyroid cancer cells.
Allegri L; Rosignolo F; Mio C; Filetti S; Baldan F; Damante G
J Cancer Res Clin Oncol; 2018 Feb; 144(2):285-294. PubMed ID: 29197967
[TBL] [Abstract][Full Text] [Related]
34. miR-148a inhibits self-renewal of thyroid cancer stem cells via repressing INO80 expression.
Sheng W; Chen Y; Gong Y; Dong T; Zhang B; Gao W
Oncol Rep; 2016 Dec; 36(6):3387-3396. PubMed ID: 27779717
[TBL] [Abstract][Full Text] [Related]
35. A case of osteoclastic variant of anaplastic thyroid carcinoma: Diagnostic and prognostic marker studies by cytology.
Bantumilli S; Zhu LC; Sakthivel M; Dodd L
Diagn Cytopathol; 2022 Dec; 50(12):E357-E360. PubMed ID: 35929756
[TBL] [Abstract][Full Text] [Related]
36. The genomic and transcriptomic landscape of anaplastic thyroid cancer: implications for therapy.
Kasaian K; Wiseman SM; Walker BA; Schein JE; Zhao Y; Hirst M; Moore RA; Mungall AJ; Marra MA; Jones SJ
BMC Cancer; 2015 Dec; 15():984. PubMed ID: 26680454
[TBL] [Abstract][Full Text] [Related]
37. Response to RET-Specific Therapy in
Dias-Santagata D; Lennerz JK; Sadow PM; Frazier RP; Govinda Raju S; Henry D; Chung T; Kherani J; Rothenberg SM; Wirth LJ
Thyroid; 2020 Sep; 30(9):1384-1389. PubMed ID: 32292131
[No Abstract] [Full Text] [Related]
38. Substantial intrinsic variability in chemoradiosensitivity of newly established anaplastic thyroid cancer cell-lines.
Gretarsson S; Nygren A; Rosendahl AH; Mylona N; Kjellén E; Jin Y; Paulsson K; Borg Å; Brun E; Tennvall J; Bergenfelz A; Greiff L; Wennerberg J; Ekblad L
Acta Otolaryngol; 2020 Apr; 140(4):337-343. PubMed ID: 31922436
[No Abstract] [Full Text] [Related]
39. Loss of MADD expression inhibits cellular growth and metastasis in anaplastic thyroid cancer.
Saini S; Sripada L; Tulla K; Kumar P; Yue F; Kunda N; Maker AV; Prabhakar BS
Cell Death Dis; 2019 Feb; 10(2):145. PubMed ID: 30760700
[TBL] [Abstract][Full Text] [Related]
40. Anaplastic thyroid cancer: cytogenetic patterns by comparative genomic hybridization.
Miura D; Wada N; Chin K; Magrane GG; Wong M; Duh QY; Clark OH
Thyroid; 2003 Mar; 13(3):283-90. PubMed ID: 12729478
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
